SoftOx Solutions

Stocks

SOFTX

NO0010811961

Market Closed - Oslo Bors Other stock markets 10:45:00 2026-07-03 EDT			5-day change	1st Jan Change
0.1010 ^NOK	-2.32%		-10.46%	+15.03%

06-26	SoftOx Solutions AS Reports Positive Topline Safety Data from SIS-03 Dose-Escalation Phase	CI
06-24	SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Transcript : SoftOx Solutions AS - Special Call

Published on 09/08/2025 at 06:20 am EDT - Modified on 09/08/2025 at 11:37 am EDT

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Obaid Saleem (Attendees)

Hello, and welcome to this webcast. Today, we have with us SoftOx Solutions in connection with an investor update. My name is Obaid Saleem, and I'm the Founder

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about SoftOx Solutions

06-26	SoftOx Solutions AS Reports Positive Topline Safety Data from SIS-03 Dose-Escalation Phase	CI
06-24	SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
06-08	SoftOx Solutions AS announced that it expects to receive NOK 6.029468 million in funding from Long State Investments Limited	CI
06-08	SoftOx Solutions AS Announces Completion of Dose-Escalation Part of the SIS-03 Phase 2a Clinical Program	CI
06-05	SoftOx Solutions AS Enrolls First Participant In SIS-02 Phase 1 Clinical Study	CI
06-05	SoftOx Solutions Enrolls First Patient in Clinical Trial of Inhalation Therapy	MT
04-13	Softox Solutions Issues Shares to Long State Investments Under Committed Financing Facility Deal	MT
04-12	SoftOx Solutions AS announced that it expects to receive NOK 7.2 million in funding from Long State Investments Limited	CI
03-25	SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-03	Softox Solutions as Announces First Subject Dosed in Combined Phase 2A Dose-Escalation and Proof-Of-Concept Trial	CI
02-25	Health Products Regulatory Authority Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy	CI
12-29	Danish Medicines Agency Approves Phase 2A Trial for Softox Inhalation Solution	CI
12-29	SoftOx Solutions Lands Approval for Inhalation Therapy's Mid-stage Study in Denmark	MT
11-28	SoftOx Solutions Issues 60 Million Shares to Long State Investments	MT
11-28	Softox Solutions resolved on private placement	RE

Chart SoftOx Solutions

Duration

Period

SOFTX: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data